This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
186
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
The change from baseline in forced vital capacity (FVC) at week 12
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness
Time frame: day 1 and week 12
Relative change from baseline in FVC at week 12
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness
Time frame: day 1 and week 12
The change from baseline in percentage predicted forced vital capacity ( ppFVC) at week 12
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness
Time frame: day 1 and week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo matching HSK44459 taken orally twice daily in the morning and in the evening for 12 weeks.